Claris Lifesciences has received an approval for the sale and transfer of the equity shares of Otsuka Pharmaceutical India (formerly knowns as Claris Otsuka) to Otsuka Pharmaceutical Factory, Inc for a consideration of $20 million. The board of directors at their meeting held on May 8, 2017 has approved for the same.
Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly- owned subsidiary dealing in Speciality Injectables business and has a minority stake in Claris Otsuka. Claris has a total of 11 approved products in the US, around 25 ANDAs under review with the FDA and markets its products in 75+ countries.
